Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Fianlimab + Linvoseltamab |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Fianlimab | REGN 3767|R3767|REGN3767 | Immune Checkpoint Inhibitor 150 LAG3 Antibody 19 | Fianlimab (REGN3767 ) is a monoclonal antibody that targets LAG3, potentially resulting in increased anti-tumor immune response (PMID: 31395688). | |
| Linvoseltamab | Lynozyfic | REGN5458|REGN-5458|REGN 5458|Anti-BCMA/CD3 BiTE|linvoseltamab-gcpt | CD3 Antibody 119 TNFRSF17 Antibody 22 | Lynozyfic (linvoseltamab) is a bispecific antibody that binds to TNFRSF17 (BCMA) and CD3 with potential antitumor activity (Blood (2019) 134 (Supplement_1): 3176). Lynozyfic (linvoseltamab) is FDA-approved for use in patients with previously-treated relapsed or refractory multiple myeloma (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05137054 | Phase I | Cevostamab + Linvoseltamab Cemiplimab + Linvoseltamab Linvoseltamab + Nirogacestat Isatuximab + Linvoseltamab Fianlimab + Linvoseltamab Lenalidomide + Linvoseltamab Bortezomib + Linvoseltamab Linvoseltamab + Pomalidomide Daratumumab + Linvoseltamab Carfilzomib + Linvoseltamab | REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Participants With Relapsed/Refractory Multiple Myeloma | Recruiting | USA | ISR | GRC | FRA | ESP | 0 |
CKB BOOST